Join to access to all OVN content. Join for Free
Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview?

Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview?


Share This Article


Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview? 🧑‍⚕️🎤

If you’re an Aspiring MSL, you likely realize how important the MSL presentation is during the final interview. But you may be wondering, “What type of presentation should I do? 🤔"

So, for this Aspiring MSL Insight, Michael Pietrack describes the top three types of MSL presentations that are acceptable in a final interview.

1️⃣ The most common type of presentation used in MSL interviews is the clinical data presentation. 📊 This is a good style to showcase your ability to understand and communicate scientific data effectively. If this is the route you take, choose a recent, relevant study and provide a comprehensive overview, including the study design, methodology, results, and implications. So, the most common type is a clinical data presentation.

2️⃣ The second most common presentation type is a therapy overview presentation. 💊 This type of presentation will showcase your knowledge of the therapeutic area and the company’s products, because you’ll be providing an in-depth overview of a particular drug’s mechanism of action or how that drug fits into the current treatment landscape. So, the second type is a therapy overview.

3️⃣ The third most common type of presentation given at a final interview for an MSL job is a journal club style presentation. 📚 In the pharmaceutical industry, a jour nal club is a formal meeting where individuals (typically healthcare professionals, researchers, or members of a pharmaceutical company) gather to critically evaluate and discuss recent articles from scientific journals. If you go this route, choose a recent and relevant article from a highly-respected journal that addresses a significant question or an advancement in the field.

Subscribe to the channel

Follow Michael Pietrack on LinkedIn

Join our private LinkedIn Job Board: "KBIC Jobs - Medical Affairs"

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Article
Real-World Evidence in Oncology: Opportunities and Limitations
OVN Avatar Massimo Di Maio, Francesco Perrone, Pierfranco Conte

Real-World Evidence in Oncology: Opportunities and Limitations

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives
OVN Avatar Jaques van Heerden, MD, Mohamed Zaghloul, MD, Anouk Neven, MSc, Teresa de Rojas, MD, PhD, Jennifer Geel, MD, Catherine Patte, MD, Joyce Balagadde-Kambugu, MD, Peter Hesseling, MD, Francine Tchintseme, MD, Eric Bouffet, MD, and Laila Hessissen, MD

Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Explore OVN